These results demonstrate the importance of SLFN11 in response to DDAs and suggest the importance of testing SLFN11 expression as a predictive biomarker, with a potential benefit for a large number of patients with multiple cancer types treated with DDAs. Here, SLFN11 is linked to cancer.